Prostaglandin I2 and thromboxane B2 biosynthesis and haemodynamic effects of lisinopril.
Minuz
P
P
Istituto di Clinica Medica, University of Verona, Italy.
Arosio
E
E
Pancera
P
P
Priante
F
F
Ribul
M
M
Degan
M
M
Lechi
A
A
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D003187:Compliance; D004311:Double-Blind Method; D004656:Enalapril / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D011464:Epoprostenol / Q000096:biosynthesis*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D007052:Ibuprofen / Q000627:therapeutic use; D017706:Lisinopril; D008297:Male; D008875:Middle Aged; D013929:Thromboxane B2 / Q000096:biosynthesis*; D014655:Vascular Resistance / Q000187:drug effects
D000806:Angiotensin-Converting Enzyme Inhibitors; D013929:Thromboxane B2; D004656:Enalapril; D011464:Epoprostenol; D017706:Lisinopril; D007052:Ibuprofen